Cytokinetics, Incorporated (CYTK)

Cytokinetics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-784.96	-589.53	-526.24	-388.96	-215.31
Depreciation & Amortization	10.13	9.53	11.89	5.81	2.28
Stock-Based Compensation	112.29	97.84	72.07	47.85	26.83
Other Adjustments	188.21	50.56	25.07	60.48	35.23
Change in Receivables	-1.11	-15.37	-1.14	56.67	-47.4
Changes in Accounts Payable	2.66	-4.48	-3.48	4.52	1.06
Changes in Accrued Expenses	33.6	14.18	17.1	10.84	15.06
Changes in Unearned Revenue	-50.76	52.37	-	-87	-
Changes in Other Operating Activities	-20.02	-11.04	-9.4	-9.74	39.74
Operating Cash Flow	-510.01	-395.89	-414.33	-299.52	-142.52
Capital Expenditures	-24.81	-3.91	-1.42	-11.34	-48.87
Purchases of Investments	-1,068	-1,293	-635.21	-855.39	-525.04
Proceeds from Sale of Investments	1,110	744.23	875.88	604.59	426.14
Investing Cash Flow	16.67	-553.1	239.25	-262.13	-147.78
Long-Term Debt Issued	-	729.46	-	523.59	-
Long-Term Debt Repaid	-413.31	-8.68	-	-187.98	-
Net Long-Term Debt Issued (Repaid)	-413.31	720.78	-	335.61	-
Issuance of Common Stock	649.18	146.66	182.69	17.54	324.43
Repurchase of Common Stock	-2.47	-19.63	-10.52	-9.6	-4.45
Net Common Stock Issued (Repurchased)	646.72	127.03	172.18	7.94	319.98
Other Financing Activities	174.8	199.06	49.14	172.62	-
Financing Cash Flow	524.46	930.61	221.32	516.17	319.98
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0.72	0.21	-0.02	-	-
Net Cash Flow	30.4	-18.17	46.22	-45.48	29.68
Free Cash Flow	-534.82	-399.8	-415.75	-310.85	-191.39
FCF Margin	-607.48%	-2164.10%	-5521.24%	-328.64%	-271.76%
Free Cash Flow Per Share	-4.45	-3.57	-4.31	-3.46	-2.49
Levered Free Cash Flow	-1,247	187.91	-511.54	-140.25	-206.06
Unlevered Free Cash Flow	-661.45	-479.59	-481.5	-411.1	-177.05

Updated Feb 24, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q